ESG Data Table

The data are basically on a non-consolidated basis.

ISO26000 Core Subject

Organizational Governance

Reported Items Unit FY2022 FY2021 FY2020
Management Structure
Executive Committee Times 11 11 11
Board of Directors Times 18 22 21
Attendance Rate of Board of Directors ％ 99.21 98.96 100
Directors Persons 9 9 8
Of which, Outside Directors Persons 4 4 3
Of which, Female Directors Persons 1 1 1
Amount of Remuneration and the Like Millions of Yen 326 392 391
Principal Activities of Outside Directors
Yutaka Atomi ー He attended all twenty-two (22) meetings held by the Board of Directors during
the fiscal year under review, and made statements at those meetings, primarily
from the professional standpoint of a medical doctor. 		He attended all twenty-one (21) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily from the professional standpoint of a medical doctor.
Saeko Arai She attended all eighteen (18) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on her extensive experience as a corporate executive and from the professional standpoint of a certified public accountant. She attended all twenty-two (22) meetings held by the Board of Directors during
the fiscal year under review, and made statements at those meetings, primarily
based on her extensive experience as a corporate executive and from the
professional standpoint of a certified public accountant. 		She attended all twenty-one (21) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on her extensive experience as a corporate executive and from the
professional standpoint of a certified public accountant.
Nobuhiro Endo He attended all eighteen (18) meeting held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on his extensive experience and a broad perspective as a corporate executive. He attended all twenty (20) of the twenty-two (22) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily
based on his extensive experience and broad perspective as a corporate executive. 		He attended all twenty-one (21) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on his extensive experience and broad perspective as a corporate executive.
Minoru Usui He attended all eighteen (18) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on his extensive experience and broad perspective as a corporate executive. He attended all seventeen (17) meetings held by the Board of Directors during the fiscal year under review after his assumption of office as a Director, and made statements at those meetings, primarily based on his extensive experience and broad perspective as a corporate executive. ー
Koji Fujimoto He attended all fifteen (15) meetings held by the Board of Directors during the fiscal year under review after his assumption of office as a Director, and made statements at those meetings, primarily based on his extensive experience and broad perspective in the healthcare field at administrative organizations. ー ー
Audit System
Audit & Supervisory Board Times 13 13 13
Audit & Supervisory Board Members Persons 5 5 5
Of which, Outside Audit & Supervisory Board Members Persons 3 3 3
Amount of Remuneration and the like Millions of Yen 93 89 87
Full-time Staff of Corporate Audits' Office Persons 1 1 1
Principal Activities of Outside Audit Supervisory Board
Junsuke Fujii ー He attended all twenty-two (22) meetings held by the Board of Directors and all thirteen (13) meetings held by the Audit & Supervisory Board during the fiscal year under review.
He made statements at
those meetings, primarily based on his extensive experience and broad perspective as a corporate executive. 		He attended twenty (20) meetings out of the twenty-one (21) meetings held by the Board of Directors and all thirteen (13) meetings held by the Audit &
Supervisory Board during the fiscal year under review. He made statements at those meetings, primarily based on his extensive experience and broad perspective as a corporate executive.
Yoshio Iteya He attended seventeen (17) meetings out of the eighteen (18) meetings held by the Board of Directors and all thirteen (13) meetings held by the Audit & Supervisory Board during the fiscal year under review. He made statements at those meetings, primarily from the professional standpoint of an attorney. He attended all twenty-two (22) meetings held by the Board of Directors and all
thirteen (13) meetings held by the Audit & Supervisory Board during the fiscal year under review. He made statements at those meetings, primarily from the professional standpoint of an attorney. 		He attended all twenty-one (21) meetings held by the Board of Directors and all thirteen (13) meetings held by the Audit & Supervisory Board during the fiscal year under review. He made statements at those meetings, primarily from the
professional standpoint of an attorney.
Mayumi Mochizuki She attended seventeen (17) meetings out of the eighteen (18) meetings held by the Board of Directors and all thirteen (13) meetings held by the Audit & Supervisory Board during the fiscal year under review. She made statements at those meetings, primarily from the
professional standpoint as a pharmacologist. 		She attended eleven (11) meetings out of the seventeen (17) meetings held by the Board of Directors and eight (8) meetings out of the ten (10) meetings held by the Audit & Supervisory Board during the fiscal year under review after her assumption of office as an Audit & Supervisory Board Member. She made statements at those meetings, primarily from the professional standpoint as a pharmacologist. ー
Daishiro Michimori He attended all fifteen (15) meetings held by the Board of Directors and all ten (10) meetings held by the Audit & Supervisory Board during the fiscal year under review after his assumption of office as an Audit & Supervisory Board Member. He made statements at those meetings, primarily from the professional standpoint of an expert in financial and accounting affairs and of an attorney. ー ー
Communication about Compliance
Corporate CSR Blog Articles 2 3 6
Framework for Compliance Implementation
Periodic Report at Board of Directors Times 1 1 1
Compliance Committee Times 1 1 1
Compliance Committee of Group Companies in Japan Times 1 1 1
Compliance Committee of Group Companies outside Japan Times 1 1 1
Whistle-blowing Systems, Consultation Desks
Systems
for All Employees		 Systems 6 7 7
Consulted Issues Cases 37 41 44
Compliance Education and Training
Compliance Trainings
for All Employees		 Times 5 2 1
Compliance Workshops Held at the Workplace Level
for All Workplaces 		Times 1 1 1
Compliance Workshops Held at the Group Companies
for all Group Companies 		Times 1 1 1
Harmful Incident Concerning Pharmaceuticals Workshops
for All Workplaces 		Times 1 1 1
Information Security Training
for All Employees		 Times 1 1 1
Stress Check
for All Employees		 Times 1 1 1
Mental Health Manager Workshops Times 1 1 1
Mental Health Self-care Workshops Times 1 1 1
Product Recall Training in Corporate Regulatory Compliance & Quality assurance Division Times 1 1 0
Natural Disaster Training in Risk Management Related Divisions Times 3 1 1
R&D Ethics e-Learning
*For researchers who are recommended to take the course on the job 		Times 1 1 1

Human Rights

Reported Items Unit FY2022 FY2021 FY2020
Initiative to Respect Human Rights
Human Rights Workshops
for All Employees		 Times 1 1 1
Drug-induced Suffering Workshops
for All Employees 		Times 1 1 1
Supply Chain Human Rights Management Workshop Times 0 0 0
Initiative to Prevent Harrasment
Number of People in Charge of the General Consultation Desk Staffs 2 2 2
Number of People in Charge of the Harassment Consultation Desk
(Internal Company) 		Staffs General Desk, 3 Staffs
Working Place Desk, 7 Sites,
17 Staffs 		General Desk, 3 Staffs
Working Place Desk, 7 Sites,
17 Staffs 		General Desk, 3 Staffs
Working Place Desk, 7 Sites,
17 Staffs
Number of People in Charge of the Harassment Consultation Desk
(Workers Union) 		Staffs General Desk, ４ Staffs
Working Place Desk, 11 Sites,
11 Staffs 		General Desk, 5 Staffs
Working Place Desk, 11 Sites,
11 Staffs 		General Desk, 5 Staffs
Working Place Desk, 11 Sites,
11 Staffs

Labour Practices

  • The social performance indicators marked with has received third-party assurance.
Reported Items Unit FY2022 FY2021 FY2020
Basic Human Resources Data
Number of Employees (consolidated)
*As of March 31 		Persons 6250 6987 6822
Men Persons 3718 4147 4119
Women Persons 2532 2840 2703
Proportion of Women ％ 40.5 40.6 39.6
Number of Employees (non-consolidated)
*As of March 31 		Persons 3026 3040 3067
Men Persons 2260 2292 2337
Women Persons 766 748 730
Proportion of Women ％ 25.3 24.6 23.8
Proportion of Female Managers
*As of April 1 of the following fiscal year 		％ 14.4 16 14.6
Gender Wage Gap (all workers) ％ 81.3 ー ー
Gender Wage Gap (permanent workers) ％ 82.5 ー ー
Gender Wage Gap (part time workers and fixed-term workers) ％ 79 ー ー
MRs in Japan, Including Managers Persons 1140 1220 1270
MRs in Japan, Excluding Managers Persons 1040 1110 1150
Average Age Age 43.8 43.4 43.1
Average Length of Continuous Employment Years 18.3 18 17.8
Recruitment of New Graduates Persons 70 64 66
Propotion of Women, New Graduates % 51.4 53.1 47
Recruitment of Mid Carrer Persons 41 29 44
Proportion of Recruitment of Mid Carrer % 36.9 31.2 40
Employment Rate of Persons with Disabilities
*As of June 1, every fiscal year 		％ 2.34 2.34 2.25
Employee Turnover Rate of Employees Leaving for Personal Reasons ％ 2.67 1.68 1.17
Retention Rate of New Graduates 3 Years after Joining the Company ％ 87.9 94.3 100
Labour Union Participating Rate Eligibility Conducted by Collective Agreement
Article 3-1 		％ 100 100 100
Total Actual Working Hours
per year		 Hours 1849.5 1871.5 1862.3
Average Overtime Hours per month Hours 4 4.1 3.3
Avarage Usage of Paid Leave Days per a Employee 15.4 14.1 13
Paid Leave Acquisition Rate ％ 77.5 70 64
Male Employees Taking Childcare Leave (note1) Persons 95 83 32
Childcare Leave Usage Rate (Male Employees) ％ 130.1 97.6 42.1
Female Employees Taking Childcare Leave Persons 26 51 33
Utilization of Shorter Working Hours for Childcare Persons 83 66 60
Utilization of Leave for Nursing Care Persons 1 1 1
Utilization of Shorter
Workdays for Nursing Care 		Persons 2 1 2
Mental Illness Leave（≧30days） Persons 17 25 6
Health and Safety Management
Stress Check for All Employees Times 1 1 1
Mental Health Manager Workshops Times 1 1 1
Mental Health Self-care Workshops Times 1 1 1
No-Overtime Day at Workplace Level Days Established at Each Workplace Established at Each Workplace Established at Each Workplace
Whole Company No-Overtime Day Days 1 1 1
Work-related Accident Frequency Rate (non-consolidated) ー
  • 0.97
 1.27 0.80
Work-related Accident Frequency Rate (non-consolidated)
＊Excluding Accidents Involving Business Vehicles 		ー
  • 0.81
 0.79 0.00
Lost-time Injuries Frequency Rate (non-consolidated) ー
  • 0.32
 0.16 0.00
Lost-time Injuries Frequency Rate (non-consolidated)
＊Excluding Accidents Involving Business Vehicles 		ー
  • 0.16
 0.16 0.00
Lost-time Injuries Frequency Rate (consolidated) ー
  • 0.44
 0.22 0.08
Lost-time Injuries Frequency Rate（contractors） ー
  • 0.00
 1.36 0.00
Fatalities (consolidated) Persons
  • 0
 0 0
Fatalities（contractors） Persons
  • 0
 0 0
Communication with Employees
Employee Engagement Survey Times 1 1 1
Response Rate ％ 98.5 98.8 98.8
Opinions toward Management Cases 757 778 1063
Proposals Made to Address Issues and/or Offer Solutions at Respective Divisions/Departments Cases 911 986 1436
  • ＊1Regarding the gender wage gap, our wage system is based on the grade of the role (job) in which each employee is engaged, and there is no difference in base wages for male and female employees in the same grade; however, the following factors contribute to the differences in their average annual wages. Employees who do not receive their wages due to absenteeism, absence from work or temporary retirement are excluded from the calculation. Among permanent workers, the fact that the percentage of female employees in general office work positions is higher than that of male employees is the main factor in the gender wage gap. As for part time workers and fixed-term workers, the majority of them are part time workers; and, the wage levels for part time workers are lower than those for employees rehired after retirement and contract workers, due to reasons such as differences in job level and working hours. The fact that these part time workers are all female workers is a factor contributing to the gender wage gap.
  • ＊2The number of employees excluding seconded employees is listed.

The Environment

  • The environmental performance indicators marked with has received third-party assurance.
Reported Items Unit FY2022 FY2021 FY2020
Environmental Management
Environmental and Safety Committee Times 2 3 2
Executive Environmental and Safety Board Times 2 2 2
Environment, Health and Safety Audit Business units 4 6 4
Follow-up Activities for Environmental and Safety Audit Cases 8 16 10
Environmental Accidents Incidents 0 0 0
Violation of Environmental Laws and Regulations Involving Criminal or Non-Criminal Fines Incidents 0 0 0
Energy Consumption*1
Total Energy Consumption MWh
  • 280835
 261238 238384
Non-renewable Energy Consumption MWh 246663 254219 238295
Renewable Energy Consumption MWh
  • 34172
 7019 89
Amount of Purchased Electricity Derived from Renewable Energy Sources MWh 34083 6933 －
Amount of Generated Electricity at the Solar Power Generating Systems*2 MWh 89 86 89
CO2 Emissions
Scope 1 (from Energy Sources)＋Scope 2 (Market-Based)
Total Emissions 		t-CO2
  • 54347
 61749 58267
Scope 1 (from Energy Sources) Emissions t-CO2
  • 27829
 21398 19514
Scope 2 (Market-Based) Emissions t-CO2
  • 26518
 40351 38753
Scope 3 Emissions *3 t-CO2 364869 382293 393124
Category 1 （Purchased Goods and Services）*4 t-CO2
  • 310925
 332970 344160
Category 2 （Capital goods）*4 t-CO2 24134 19015 19669
Category 3 （Fuel- and Energy-Related Activities not Included in Scope 1 or Scope 2）*3 t-CO2 15048 15643 15793
Category 4 (Upstream Transportation and Distribution) t-CO2 853 824 860
Category 5 （Waste Generated in Operations） t-CO2 3655 4466 1943
Category 6 （Business Travel） t-CO2 3140 886 554
Category 7 （Employee Commuting） t-CO2 634 651 732
Category 8 （Upstream Leased Assets） t-CO2 － － －
Category 9 （Downstream Transportation and Distribution）*5 t-CO2 3555 3344 4204
Category 10 （Processing of Sold Products） t-CO2 － － －
Category 11 （Use of Sold Products） t-CO2 2521 4065 4770
Category 12 （End-of-Life Treatment of Sold Products） t-CO2 302 323 335
Category 13 （Downstream Leased Assets） t-CO2 103 106 104
Category 14 （Franchises） t-CO2 － － －
Category 15 （Investments） t-CO2 － － －
Amount of Water Withdrawal and Wastewater Discharged
Total Amount of Water Withdrawal（consolidated) t
  • 847157
 873171 889692
Tap Water（consolidated) t
  • 342057
 397701 341140
Industrial Water（consolidated) t
  • 377879
 408387 393987
Ground Water（consolidated)*6 t
  • 113045
 55853 142183
Other（consolidated) t
  • 14176
 11230 12382
Total Amount of Water Withdrawal (non-consolidated) t 804281 814250 821090
Tap Water (non-consolidated) t 299181 338780 272538
Industrial Water (non-consolidated) t 377879 408387 393987
Ground Water (non-consolidated)*6 t 113045 55853 142183
Other (non-consolidated) t 14176 11230 12382
Total Amount of Water Discharged（consolidated) t
  • 843300
 866398 883402
River（consolidated) t 589817 604448 616743
Sewerage（consolidated) t 253483 261950 266659
Total Amount of Water Discharged (non-consolidated) t 804281 814250 821090
River (non-consolidated) t 589817 604448 616743
Sewerage (non-consolidated) t 214464 209802 204347
Raw Material Consumption
Raw Materials for Products (Excluding Metals) t 2861 3577 3997
Raw Materials for Products (Metals) t 1 0 10
Total Amount of Product Containers and Packaging Materials t 590 642 658
Glass t 53 55 54
Plastic t 332 354 367
Paper t 204 234 236
PRTR Substances and VOC Substances Handled
PRTR Substances t 958 1417 1545
VOC Substances t 2004 2452 3215
Waste
Total Amount of Waste Generated t 4757 6183 7685
Amount Recycled t 3442 4717 6133
Recycling Rate ％ 72 76 80
Amount of Final Disporsal t 14 18 56
Final Disposal Rate ％ 0 0 1
Amount of Hazardous Waste Generated t 3603 5196 6402
Amount of Hazardous Waste Recycled t 3069 4408 5821
PRTR Substances t 930 1371 1453
Waste Containing High Levels of PCB in Storage Units 0 0 1
Waste Containing Low Levels of PCB in Storage or in Use Units 4 4 4
Released into the Atmosphere
SOX t 0.2 0.3 0.2
NOX t 31.6 37.5 42.2
Dust Emissions t 0.1 0.2 0.2
PRTR Substances t 2.7 3.0 5.3
VOC Substances t 14.8 17.3 22.8
Released into Water Systems
BOD t 0.2 0.2 0.2
COD t 2.0 2.2 2.2
Phosphorus t 0.1 0.1 0.1
Nitrogen t 0.4 0.5 0.3
PRTR Substances t 0.0 0.0 0.0
Environmental Accounting
Environmental Investment Millions of Yen 137 226 16
Environmental Expenditure Millions of Yen 698 772 731
Economic Effect Millions of Yen 3 3 3
Application of Environmental Conservation Systems
Green Procurement (Green Purchasing Ratio of Office Supplies) ％ 51 53 53
Green Logistics Initiatives 39 46 67
Green Product Development Initiatives 37 37 30
Green Facilities Design Initiatives 16 13 15
Environmental Considerations for Business Vehicles
Percentage of Business Vehicles Shifted to Hybrid Cars (Excluding Cold Regions) ％ 100 100 100
Number of Electric Vehicles (EVs) in Our Business Vehicles Vehicles 11 11 0
Communications with Group Companies
Meeting to Exchange Information on Environment and Safety between Group Companies in Japan Times 1 1 1
Environment, Health and Safety Audits Conducted for Group Companies in Japan Companies 0 2 2
Environment, Health and Safety Audits Conducted for Group Companies Outside Japan Companies 0 0 0
Biodiversity
Owls Forest Restoration Project of Kishiwada City, Osaka Times
Participants		 6
128		 1
13*7 		2
20*7
  • ＊1The unit of energy consumption was changed from TJ to MWh in FY2022. At this time, the units for previous years were also changed.
  • ＊2The amount of solar power generation from FY 2020 to 2022 shows only the amount of solar power generation at the Central Research Laboratories due to measuring instrument failure at the Osaka Research Center.
  • ＊3Some of the figures for FY2020 and FY2021 have been corrected.
  • ＊4In Japanese Ministry of the Environment's "The database on emissions unit values for accounting of greenhouse gas emissions, etc. by organizations throughout the supply chain" (ver. 3.3), it was (newly) specified that the consumption tax is included in the emission intensity. Therefore, we calculated the figures for FY2022 by taking into account the consumption tax. As for the figures for FY2021 or earlier, we did not take into account the consumption tax when calculating the figures; however, we have not revised them as their impact is not significant.
  • ＊5CO2 emissions from pharmaceutical wholesalers in FY2022 are not publicly available. Therefore, CO2 emissions from pharmaceutical wholesalers in FY2021 were used in the calculation of CO2emissions in FY2022. As for the sales of pharmaceutical wholesalers and the sales of our products in pharmaceutical wholesalers, the sales in FY2022 were used.
  • ＊6The figures for FY2021 do not include 18,149 tons* of groundwater that was pumped up but not used and then discharged.
    (*) Difference between raw water and treated water in the period between June and October 2021 (5 months) when groundwater use was suspended.
  • ＊7We refrained from the activities to prevent the spread of COVID-19.

Fair Operating Practices

Reported Items Unit FY2022 FY2021 FY2020
Appropriate Information Disclosure and Management
Information Security Training
for All Employees		 Times 1 1 1
Violations of Code of Conduct
Number of Serious Compliance
Violations		 Times 0 0 0

Consumer Issues

Reported Items Unit FY2022 FY2021 FY2020
Initiatives to Provide Stable Supplies
Factory in Japan Sites 2 2 2
Distribution Center in Japan Sites 2 2 2
Initiatives to Ensure Safety of Pharmaceuticals
Product Recall Training in Corporate Regulatory Compliance & Quality assurance Division Times 1 1 0
Harmful Incident Concerning Pharmaceuticals Workshops
for all Employees 		Times 1 1 1
Initiatives to Improve Access to Medicines
Responding to Demands for Development of Unapproved or Off-Label Drugs Projects 2 2 1
Collaborative Programs with Public Institutions to Control Malaria, Influenza, Antimicrobial Resistance (AMR) and Hepatitis B Projects 7 7 6
Fight against Counterfeit Pharmaceuticals in Collaboration with International Organizations Projects 1 1 1
Communication with Customers
Inquiries to the Product Information Center Times about 30,400 about 34,000 about 41,500

Community Involvement and Development

Reported Items Unit FY2022 FY2021 FY2020
Stakeholder Dialogue
Dialogue with Patients and Families
Inquiries to the Product Information Center Times 1800 1900 3800
Dialogue with Healthcare　professionals
Inquiries to the Product Information Center Times 26800 29800 34800
Dialogue with Collaboration partners
Competitive Open Innovation Program framework "PRISM"（Research Needs PresentationⅡ） Number of acceptance／Number of applications 5／59 ー ー
Competitive Open Innovation Program framework "PRISM" (Research Needs Presentation, Joint Creation by Young Researchers) Number of acceptance／
Number of applications		 ー 2／15
1 Collaboration out of PRISM		 2／15
1 Collaboration out of PRISM
Dialogue with Shareholders
Shareholders' Meeting Times 1 1 1
Financial Results Announcement Times 2 2 2
Conference Call Times 2 2 2
Meeting with Analysts and Institutional Investors Times 92 103 76
ESG Meeting Times 1 1 1
R&D Meeting Times 0 1 1
Dialogue with Employees
Employee Engagement Survey Times 1 1 1
Response Rate % 99 99 99
Opinions toward Management Cases 757 778 1063
Proposals Made to Address Issues and/or Offer Solutions at Respective Divisions/Departments Cases 911 986 1436
Supporting through Employee Participation
Educational Assistance for the Next-generation
Visiting Lectures by Employees Schools 14 7 4
Biodiversity
The Owls Forest Restoration Project at the Sumitomo Pharma Forest Times 6 1 2

Standards for Calculating Social Performance Indicators

Social Performance Indicators Scope of aggregation Calculation method, etc.
Work-related Accident Frequency Rate (Non-consolidated); Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and SMP Distribution Service Co., Ltd. in Japan Number of deaths and injuries due to occupational accidents with or without lost workdays, excluding commuting accidents, per 1,000,000 cumulative hours worked
Work-related Accident Frequency Rate
＊Excluding Accidents Involving Business Vehicles 		(Non-consolidated); Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and SMP Distribution Service Co., Ltd. in Japan Number of deaths and injuries due to occupational accidents with or without lost workdays, excluding accidents involving business vehicles and commuting accidents, per 1,000,000 cumulative hours worked
Lost-time Injuries Frequency Rate (Non-consolidated); Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and SMP Distribution Service Co., Ltd. in Japan Number of deaths and injuries due to occupational accidents with one or more lost workdays, excluding commuting accidents, per 1,000,000 cumulative hours worked
（Consolidated）；
＜FY2020 and FY2021＞
Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and the Sumitomo Pharma Group's consolidated companies in Japan and abroad (excluding one company for which an accident report was not available)
＜FY2022＞
Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and the Sumitomo Pharma Group's consolidated companies in Japan and abroad
(Contractors) ; Employees of contractors (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of the Company in Japan.
Lost-time Injuries Frequency Rate
＊Excluding Accidents Involving Business Vehicles 		(Non-consolidated); Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and SMP Distribution Service Co., Ltd. in Japan Number of deaths and injuries due to occupational accidents with one or more lost workdays, excluding accidents involving business vehicles and commuting accidents, per 1,000,000 cumulative hours worked
Fatalities （Consolidated）；
＜FY2020 and FY2021＞
Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and the Sumitomo Pharma Group's consolidated companies in Japan and abroad (excluding one company for which an accident report was not available)
＜FY2022＞
Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and the Sumitomo Pharma Group's consolidated companies in Japan and abroad 		Number of deaths due to occupational accidents
(Contractors) ; Employees of contractors (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of the Company in Japan.

Standards for Calculating Environmental Performance Indicators

●Energy Consumption

Environmental performance indicators Scope of aggregation Calculation method, etc.
Total Energy Consumption FY 2020:
Non-consolidated（Sumitomo Pharma Co., Ltd. Only)

FY2021：
 Sumitomo Pharma Co., Ltd., consolidated subsidiaries in Japan, overseas consolidated subsidiaries' production sites (Sumitomo Pharma (Suzhou) Co., Ltd.) and their major R&D facilities (Sunovion Pharmaceuticals Inc.* and Sumitomo Pharma Oncology, Inc.*)

FY2022：
Consolidated（Sumitomo Pharma Co., Ltd., consolidated subsidiaries in Japan, overseas consolidated subsidiaries)

＊Sunovion Pharmaceuticals Inc. and Sumitomo Pharma Oncology, Inc. changed their trade names to Sumitomo Pharma America, Inc. as a result of the reorganization of our U.S. group companies effective as of July 1, 2023. 		Purchased electricity＃1＋（purchased heat×unit calorific value+fuel consumption＃2× unit calorific value)÷conversion factor for "MWh" to "GJ"#3
The unit calorific values and the types of fuel to be calculated are based on the "Act on the Rational Use of Energy." In FY2022, as for overseas non-production sites for which we do not have actual energy consumption data, we have made estimates based on the energy consumption at similar sites, using floor space ratios and other factors.
#1 It includes solar power generated at our business sites.
#2 Gasoline consumption of business vehicles includes only domestic gasoline consumption for FY2021 and earlier, and all domestic and overseas gasoline consumption for FY2022 and beyond.
#3 3.6GJ/MWh
Non-renewable Energy Consumption Amount of energy consumption derived from non-renewable energy sources out of the total energy consumption
Renewable Energy Consumption Amount of energy consumption derived from renewable energy sources out of the total energy consumption
Amount of Purchased Electricity Derived from Renewable Energy Sources Amount of renewable energy-derived electricity purchased out of the renewable energy
consumption
Amount of Generated Electricity at the Solar Power Generating Systems Amount of solar power generated by solar power generation systems at our business sites out of the renewable energy consumption

●CO2 Emissions

Environmental performance indicators Scope of aggregation Calculation method, etc.
Scope 1 (from Energy Sources)＋Scope 2 (Market-Based)
Total Emissions 		FY2020:
Non-consolidated（Sumitomo Pharma Co., Ltd. Only)

FY2021:
Sumitomo Pharma Co., Ltd., consolidated subsidiaries in Japan, overseas consolidated subsidiaries' production sites (Sumitomo Pharma (Suzhou) Co., Ltd.) and their major R&D facilities (Sunovion Pharmaceuticals Inc.* and Sumitomo Pharma Oncology, Inc.*)

FY2022:
Consolidated
(Sumitomo Pharma Co., Ltd., consolidated subsidiaries in Japan, overseas consolidated subsidiaries)

＊Sunovion Pharmaceuticals Inc. and Sumitomo Pharma Oncology, Inc. changed their trade names to Sumitomo Pharma America, Inc. as a result of the reorganization of our U.S. group companies effective as of July 1, 2023.

Total of Scope 1 (from Energy Sources) and Scope 2 (Market-Based) emissions
Scope 1 (from Energy Sources) Emissions Fuel consumption #4 × fuel unit calorific value × fuel CO2 emissions factor
The unit calorific values and CO2 emissions factors are based on "Greenhouse Gas Emissions Accounting, Reporting, and Disclosure System" which is provided in the "Act on Promotion of Global Warming Countermeasures."
In FY2022, as for overseas non-production sites for which we do not have actual fuel consumption figures, we have made estimates based on the fuel consumption at similar sites, using floor space ratios and other factors.
#4Gasoline consumption of business vehicles includes only domestic gasoline consumption for FY2021 and earlier, and all domestic and overseas gasoline consumption for FY2022 and beyond.
Scope 2 (Market-Based) Emissions Purchased electricity#5×electricity CO2 emissions factor#6＋purchased heat × heat CO2 emissions factor#7
#5 It includes solar power generated at our business sites.
#6 For domestic sites, adjusted emissions factors from "Emission Factors by Power Suppliers (for the calculation of GHG emissions by specified emitters)" published by the Ministry of the Environment and the Ministry of Economy, Trade and Industry of Japan, for overseas sites, the emissions factors by country for 2019 published by the International Energy Agency (IEA). However, we use values provided by Sumitomo Chemical Co., Ltd. for sites located on the premises of Sumitomo Chemical Co., Ltd.
#7 Values are based on "Greenhouse Gas Emissions Accounting, Reporting, and Disclosure System" which is provided in "Act on Promotion of Global Warming Countermeasures." However, we use values provided by Sumitomo Chemical Co, Ltd. for sites located on the premises of Sumitomo Chemical Co., Ltd.
In FY2022, as for overseas non-production sites for which we do not have actual purchased electricity amounts, we have made estimates based on purchased electricity amounts at similar sites, using floor space ratios and other factors.
Scope3 Emissions Refer to each category Total of Category 1 emissions to Category 15 emissions
Ministry of the Environment DB: Ministry of the Environment's "Emission Intensity Database for Calculating Greenhouse Gas Emissions etc. of Organizations through their Supply Chains" (FY2020 emissions; Ver. 3.1 applied, FY2021 emissions; Ver. 3.2 applied, FY2022 emissions; Ver. 3.3 applied)
LCI-DB: LCI Database IDEAv2 (for calculation of supply chain GHG emissions)
Category 1 （Purchased Goods and Services） Non-consolidated Calculated by multiplying the purchase price of raw and packaging materials for products and purchased products and outsourced manufacturing costs by the emissions intensity in Japanese Ministry of the Environment database
Category 2 （Capital Goods） Consolidated basis (The Sumitomo Pharma Group including overseas subsidiaries) Calculated by multiplying the acquisition price of the fixed asset by the emissions intensity in Japanese Ministry of the Environment database
Category 3 （Fuel- and Energy-Related Activities not Included in Scope 1 or Scope 2） Non-consolidated Calculated by multiplying purchased electricity and steam by the emissions intensity in Japanese Ministry of the Environment database and purchased fuel by the emissions intensity in Carbon Footprint database or lifecycle inventory (LCI) database
Category 4 (Upstream Transportation and Distribution) Transport in Japan, on a non-consolidated basis Calculated by multiplying ton/kilometer for the transportation scenario by the emissions intensity in Japanese Ministry of the Environment database and LCI database
Category 5 （Waste Generated in Operations） Non-consolidated Calculated by multiplying the weight of waste according to type and processing method by the emissions intensity in Japanese Ministry of the Environment database
Category 6 （Business Travel） Non-consolidated Calculated by multiplying business travel expenses paid by the emissions intensity in Japanese Ministry of the Environment database
Category 7 （Employee Commuting） Non-consolidated Calculated by multiplying commuting cost according to transportation means by the emissions intensity in Japanese Ministry of the Environment database
Category 8 （Upstream Leased Assets） ー ー
Category 9 （Downstream Transportation and Distribution） Non-consolidated Calculated by multiplying CO2emissions (estimate) per unit of sales in major drug wholesalers by sales of our products in drug wholesale segment
Category 10 （Processing of Sold Products） ー ー
Category 11 （Use of Sold Products） Non-consolidated Calculated by multiplying HFC amount in pharmaceutical MDIs (metered dose inhalers) sold by GWP
Category 12 （End-of-Life Treatment of Sold Products） Non-consolidated Calculated by multiplying the weight of the container and packaging according to material based on "Act on the Promotion of Sorted Collection and Recycling of Containers and Packaging” by the emissions intensity in Japanese Ministry of the Environment database
Category 13 （Downstream Leased Assets） Non-consolidated Calculated by multiplying the energy consumption of the building asset owned and rented out by the conversion factors based on "Greenhouse Gas Emissions Accounting, Reporting, and Disclosure System" which is provided in "Act on Promotion of Global Warming Countermeasures"
Category 14 （Franchises） ー ー
Category 15 （Investments） ー ー

●Amount of Water Withdrawal and Wastewater Discharged

Environmental performance indicators Scope of aggregation Calculation method, etc.
Total Amount of Water Withdrawal
（consolidated)		 Consolidated
（Sumitomo Pharma Co., Ltd., consolidated subsidiaries in Japan, overseas consolidated subsidiaries)
However, small offices such as branches and business offices are excluded. In addition, overseas consolidated subsidiaries that do not have production sites or major research facilities are excluded from the scope because they have only small offices. 		Total amount of water withdrawal of tap water, industrial water, ground water, and other (pure water)
Total Amount of Water Discharged
（consolidated)		 Total amount of water discharged to rivers and to sewerage.
*As for sites that do not measure the amount of water discharged, the amount of water withdrawal is considered as the water discharged.
Total Amount of Water Withdrawal
(non-consolidated)		 Non-consolidated
（Only Sumitomo Pharma Co., Ltd.)
However, small offices such as branches and business offices are excluded. 		Total amount of water withdrawal of tap water, industrial water, ground water, and other (pure water).
Total Amount of Water Discharged
(non-consolidated)		 Total amount of water discharged to rivers and to sewerage.
*As for sites that do not measure the amount of water discharged, the amount of water withdrawal is considered as the water discharged.

●Raw Material Consumption

Environmental performance indicators Scope of aggregation Calculation method, etc.
Raw Materials for Products (excluding Metals) Non-consolidated Amount of consumed raw materials for products (excluding metals)
Raw Materials for Products (Metals) Amount of consumed raw metals for products (metals)
Product Containers and Packaging Materials Total amount of product containers and packaging materials used for products sold in Japan

●PRTR Substances and VOC Substances

Environmental performance indicators Scope of aggregation Calculation method, etc.
PRTR Substances Non-consolidated Amount of PRTR substances handled for which we submitted reports under the Japanese Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the environment and Promotion of Improvements to the Management Thereof (PRTR Law)
VOC Substances Total amount of substance annually handled in quantities of 1 ton or more, out of 55 substances*
*The number of substances excluding PRTR substances, out of 101 volatile organic compounds (VOCs), i.e. the 100 major VOCs listed by the Ministry of the Environment plus n-propyl alcohol

●Waste

Environmental performance indicators Scope of aggregation Calculation method, etc.
Total Amount of Waste Generated Non-consolidated
However, branches and business offices are excluded. 		Total amount of by-products and other unwanted materials generated as a result of our normal business activities (including valuable resources)
Amount Recycled Amount of waste reused, recycled, or converted to valuable resources out of the total amount of waste generated
Recycling Rate Percentage of amount of waste recycled to the total amount of waste generated
Amount of Final Disporsal Amount of waste finally disposed of by landfill out of the total amount of waste generated
Final Disposal Rate Percentage of waste finally disposed of to the total amount of waste generated
Amount of Hazardous Waste Generated Amount of hazardous waste (waste classified as specially-controlled industrial waste generated) out of the total amount of waste generated
Amount of Hazardous Waste Recycled Amount of hazardous waste reused, recycled, or converted into valuable resources out of the total amount of hazardous waste generated
PRTR Substances Non-consolidated Atmospheric emission of PRTR substances that we reported under the PRTR Law
Waste Containing High Levels of PCB in Storage Non-consolidated Total amount/number of waste containing high levels of PCB in storage
Waste Containing Low Levels of PCB in Storage or in Use Total number of devices containing low levels of PCB that are stored or continuously used

●Other Indicators

・The data are basically on a non-consolidated basis.